These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 2161885

  • 41. Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site.
    Myones BL, Ross GD.
    Complement; 1987; 4(2):87-98. PubMed ID: 3497773
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Characterization of the EBV/C3d receptor on the human Jurkat T cell line: evidence for a novel transcript.
    Sinha SK, Todd SC, Hedrick JA, Speiser CL, Lambris JD, Tsoukas CD.
    J Immunol; 1993 Jun 15; 150(12):5311-20. PubMed ID: 8390533
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. CR2 ligands modulate human B cell activation.
    Bohnsack JF, Cooper NR.
    J Immunol; 1988 Oct 15; 141(8):2569-76. PubMed ID: 2459218
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL.
    Delibrias CC, Fischer E, Bismuth G, Kazatchkine MD.
    J Immunol; 1992 Aug 01; 149(3):768-74. PubMed ID: 1386093
    [Abstract] [Full Text] [Related]

  • 49. Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells.
    Martin DR, Marlowe RL, Ahearn JM.
    J Virol; 1994 Aug 01; 68(8):4716-26. PubMed ID: 7913508
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Biochemical and antigenic analysis of the Epstein Barr virus/C3d receptor (CR2).
    Siaw MF, Nemerow GR, Cooper NR.
    J Immunol; 1986 Jun 01; 136(11):4146-51. PubMed ID: 3009616
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction.
    Masucci MG, Szigeti R, Ernberg I, Hu CP, Torsteinsdottir S, Frade R, Klein E.
    Eur J Immunol; 1987 Jun 01; 17(6):815-20. PubMed ID: 3036539
    [Abstract] [Full Text] [Related]

  • 56. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.
    Nemerow GR, Mullen JJ, Dickson PW, Cooper NR.
    J Virol; 1990 Mar 01; 64(3):1348-52. PubMed ID: 2154612
    [Abstract] [Full Text] [Related]

  • 57. Identification and characterization of complement C3 receptors on human astrocytes.
    Gasque P, Chan P, Mauger C, Schouft MT, Singhrao S, Dierich MP, Morgan BP, Fontaine M.
    J Immunol; 1996 Mar 15; 156(6):2247-55. PubMed ID: 8690915
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
    Frémeaux-Bacchi V, Bernard I, Maillet F, Mani JC, Fontaine M, Bonnefoy JY, Kazatchkine MD, Fischer E.
    Eur J Immunol; 1996 Jul 15; 26(7):1497-503. PubMed ID: 8766552
    [Abstract] [Full Text] [Related]

  • 60. Tissue distribution of the C3d/EBV-receptor: CD21 monoclonal antibodies reactive with a variety of epithelial cells, medullary thymocytes, and peripheral T-cells.
    Timens W, Boes A, Vos H, Poppema S.
    Histochemistry; 1991 Jul 15; 95(6):605-11. PubMed ID: 1830299
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.